On April 15, 2026, the U.S. Food and Drug Administration announced a significant update to its Bulk Drug Substances list under Section 503A. Twelve peptides — substances that had been restricted from compounding since September 2023 — were formally removed from Category 2, the agency's designation for substances identified as presenting "significant safety risks."
The announcement was immediately described across social media as a reversal, an approval, and in some cases, a green light for peptide access. The reality is more nuanced. This post is our attempt to separate what actually changed from what's being reported.
What actually happened
The FDA updated its Section 503A bulk drug substances list, providing notice that after seven days it would remove twelve peptide substances from Category 2. The stated reason was that the original nominations had been withdrawn by the nominators.
Simultaneously, the FDA published a Federal Register notice announcing two upcoming meetings of the Pharmacy Compounding Advisory Committee (PCAC): one on July 23–24, 2026, and a second before the end of February 2027. At these meetings, the committee will review whether these peptides should be formally added to the 503A bulks list — which would, in turn, permit their use in compounding.
The twelve peptides
The distinction most are missing
This is where the reporting has been most misleading, and where Intrinsic Peptides wants to be precise:
Removal from Category 2 is not the same as approval for compounding.
These twelve peptides still cannot be legally compounded by 503A pharmacies today. The PCAC must review each one individually. The committee makes recommendations. The FDA retains final authority to accept, modify, or reject those recommendations.
In short: the April 15 announcement opens a door that has been closed since September 2023. It does not walk through it.
What this means, in plain terms
How we got here
- September 2023: FDA moves 19 peptides from Category 1 to Category 2, citing immunogenicity risk, peptide-related impurities, and limited human safety data.
- February 27, 2026: HHS Secretary Robert F. Kennedy Jr. signals the administration's intent to reclassify approximately 14 of the restricted peptides, describing the 2023 decision as an overreach.
- April 15, 2026: The FDA formally removes 12 peptides from Category 2 and schedules PCAC review.
- June 30 / July 9, 2026: Deadlines for oral presentation requests and written public comments, respectively, for the upcoming PCAC meetings.
- July 23–24, 2026: First PCAC meeting convenes.
- Before end of February 2027: Second scheduled PCAC meeting.
What this means for the research community
- The regulatory path toward structured, physician-supervised access has reopened — but remains procedurally incomplete.
- Compounding pharmacies still cannot prepare these twelve peptides under current FDA policy. Enforcement risk remains until formal rulemaking is complete.
- The July 23–24 PCAC meeting is the next meaningful checkpoint. Written public comments submitted by July 9, 2026 will be provided directly to the committee.
For those in the research community, the months ahead are a rare window of regulatory attention on peptide science. The outcome of the PCAC review will shape the framework under which these substances are studied, accessed, and discussed for years to come.
Why we're watching closely
Intrinsic Peptides exists at the intersection of rigorous research and transparent education. The 2023 Category 2 designation affected the entire landscape of peptide-adjacent work. The 2026 reassessment will reshape it again.
We're committed to reporting what the FDA actually publishes — not what social media interprets. Every meaningful development between now and February 2027 will be documented here and shared with our regulation tracker subscribers.